In recent years, the AI pharmaceutical industry has been entering a prosperous golden period of development. With the rapid advancement of AI technology and the widespread application of big data, AI has shown tremendous potential and value in the field of drug development. The traditional drug development process is lengthy, costly, and has a high failure rate. The introduction of AI technology has made drug development more efficient and precise. Medicilon, as a one-stop biopharmaceutical preclinical CRO, has been actively exploring cutting-edge technologies in drug development for twenty years. In the AI pharmaceutical field, Medicilon has established an AI drug discovery platform based on collaborations with several AI innovative drug development companies such as InSilico Medicine and MindRink. Medicilon's AI technology service platform can provide protein structure prediction and simulation, binding site discovery, information extraction and cleansing, as well a...
Integrated Drug Discovery Services- Chemistry, Biology & Preclinical Services